首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Efficacy of Trovafloxacin in Treatment of Experimental Staphylococcal or Streptococcal Endocarditis
【2h】

Efficacy of Trovafloxacin in Treatment of Experimental Staphylococcal or Streptococcal Endocarditis

机译:曲伐沙星治疗实验性葡萄球菌或链球菌性心内膜炎的功效

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The efficacy of trovafloxacin against Staphylococcus aureus and viridans group streptococci was investigated in vitro and in an experimental model of endocarditis. The MICs at which trovafloxacin and ciprofloxacin inhibited 90% of clinical isolates of such bacteria (MIC90s) were (i) 0.03 and 2 mg/liter, respectively, for 30 ciprofloxacin-susceptible S. aureus isolates, (ii) 32 and 128 mg/liter, respectively, for 20 ciprofloxacin-resistant S. aureus isolates, and (iii) 0.25 and 8 mg/liter, respectively, for 28 viridans group streptococci. Rats with aortic vegetations were infected with either of two ciprofloxacin-susceptible but methicillin-resistant S. aureus strains (strains COL and P8), one penicillin-susceptible Streptococcus sanguis strain, or one penicillin-resistant Streptococcus mitis strain. Rats were treated for 3 or 5 days with doses that resulted in kinetics that simulated those achieved in humans with trovafloxacin (200 mg orally once a day), ciprofloxacin (750 mg orally twice a day), vancomycin (1 g intravenously twice a day), or ceftriaxone (2 g intravenously once a day). Against the staphylococci, the activities of both trovafloxacin and ciprofloxacin were equivalent to that of vancomycin, and treatment of endocarditis with these drugs was successful (P < 0.05). However, ciprofloxacin selected for resistant derivatives in vitro and in vivo, whereas trovafloxacin was 10 to 100 times less prone than ciprofloxacin to select for resistance in vitro and did not select for resistance in vivo. Against the two streptococcal isolates, trovafloxacin significantly (P < 0.05) decreased bacterial counts in the vegetations but was less effective than the control drug, ceftriaxone. Thus, a simulated oral dose of trovafloxacin (200 mg per day) was effective against ciprofloxacin-susceptible staphylococci and was less likely than ciprofloxacin to select for resistance. The simulated oral dose of trovafloxacin also had some activity against streptococcal endocarditis, but optimal treatment of infections caused by such organisms might require higher doses of the drug.
机译:体外和在心内膜炎的实验模型中研究了曲伐沙星对金黄色葡萄球菌和绿藻类链球菌的疗效。环丙沙星和环丙沙星抑制90%的此类细菌临床分离株(MIC90)的MIC分别为(i)0.03和2 mg / L,对30环丙沙星敏感的金黄色葡萄球菌分离株(ii)32和128 mg / L对于20株耐环丙沙星的金黄色葡萄球菌分离株,每升分别为1升和(28)vi子草群链球菌分别为(iii)0.25和8 mg /升。用两种对环丙沙星敏感但耐甲氧西林的金黄色葡萄球菌菌株(COL和P8菌株),一种对青霉素易感的血链球菌菌株或一种对青霉素耐药的链球菌致病菌感染主动脉植被的大鼠。对大鼠进行3或5天的剂量处理,所产生的动力学模拟在人类中使用曲伐沙星(每天口服200毫克),环丙沙星(每天两次口服750毫克),万古霉素(每天两次静脉注射1克)所达到的动力学。或头孢曲松(每天2 g静脉注射)。对葡萄球菌而言,曲伐沙星和环丙沙星的活性与万古霉素相当,并且用这些药物治疗心内膜炎很成功(P <0.05)。然而,环丙沙星在体外和体内均被选作耐药性衍生物,而曲伐沙星在体外选择耐药性的倾向性比环丙沙星低10至100倍,而在体内则没有选择。针对这两种链球菌分离株,曲伐沙星显着(P <0.05)减少了植被中的细菌数量,但效果不如对照药物头孢曲松。因此,模拟口服曲伐沙星(每天200 mg)可有效抵抗环丙沙星敏感的葡萄球菌,并且比环丙沙星选择耐药性的可能性更低。曲伐沙星的模拟口服剂量也对链球菌性心内膜炎具有一定的活性,但是对由此类生物体引起的感染的最佳治疗可能需要更高剂量的药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号